03 aug: SKAGEN Fondene: Lys i mørket ?
04 aug: SORT KANT – 12 COOL DESIGNHITS
04-08-2011 07:31:01

First half of 2011: Dräger continues successful trend

Drägerwerk AG & Co. KGaA /

First half of 2011: Dräger continues successful trend

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

  • Order intake and net sales up

  • EBIT margin amounts to 9.1 percent.

  • Equity ratio rises to 34 percent 

Lübeck - Drägerwerk AG & Co. KGaA's order intake and net sales increased in the first half of 2011. Order intake after the first six months of 2011 totaled EUR 1.11 billion, 6.3 percent (net of currency effects) higher than in the previous year (6 months 2010: EUR 1.05 billion). Order intake in the second quarter of 2011 developed very differently in the two divisions: While order intake in the safety division rose by 8.9 percent (net of currency effects), order intake in the medical division dropped by 2.3 percent (net of currency effects). A large order from Brazil had led to an extraordinarily high order basis in the previous year's period. Group sales rose by 2.3 percent (net of currency effects) to approximately EUR 1.03 billion in the first six months of 2011 (6 months 2010: EUR 1.02 billion).

 

Dräger invests in new products and markets

Dräger increased its gross profit by EUR 24.2 million against the first half of 2010 to approximately EUR 514.0 million, up 5.0 percent. This was mainly due to continuing strong demand from the high-margin business with industrial customers and the overall high level of capacity utilization in the safety division. However, functional costs rose disproportionately by around 9 percent. Dräger invested 12.3 percent more in research and development alone than in the previous year. "In 2011, we will invest more in future products and market potentials as well as in the expansion of sales activities", said Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. At EUR 94.5 million, Dräger's EBIT was down 8.0 percent on the previous year in the first half of 2011 (6 months 2010: EUR 102.6 million). The EBIT margin was 9.1 percent (6 months 2010: 10.1 percent). Earnings after income taxes amounted to EUR 53.7 million, down slightly on the previous year's period (6 months 2010: EUR 55.9 million).

 

Improved equity ratio

Dräger's equity rose by EUR 4.0 million to EUR 640.6 million in the first six months of 2011. This increase was mainly the result of earnings in the first half of 2011 as well as the offsetting effects of the dividend payments and the negative differences arising from currency translations at the foreign subsidiaries. The equity ratio went up to 34.0 percent (December 31, 2010: 32.2 percent). "This performance brings us a step closer to achieving an equity ratio of at least 35 percent. This is important to counter the fluctuating global economy, as is flexibility when it comes to capacities and costs," emphasized Stefan Dräger.

 

Outlook: Forecast increased in July

On July 19, 2011, Dräger increased its forecast for the current financial year. The Company now anticipates an EBIT margin between 8.0 percent and 9.5 percent (previously: 7.5 percent to 8.5 percent) - based on the unchanged assumption of slight sales growth. Dräger anticipates that order intake will grow at least as fast as the entire global economy (IMF June 2011 forecast: +4.3 percent). Net sales growth in 2011 will be one to two percentage points down on order intake growth as net sales in 2010 benefited from above-average order intake in the fourth quarter of 2009.

 

Dräger plans to invest more in product development and the Group-wide IT infrastructure. However, the costs for the new marketing and sale structure in 2011 will not come to the same figure as originally planned.

 

The estimated development of net sales and margins is based on the assumption that the markets relevant to Dräger will continue their steady development and that exchange rates will remain unchanged. Global uncertainty factors have increased further, which makes an exact forecast difficult.

 

Key figures for the first six months of 2011 (in EUR million)

  Q2 2011 Q2 2010 H1 2011 H1 2010 Change Net of currency effects
Order intake 555.5 560.7 1,109.1 1,048.9 +5.7 % +6.3 %

Medical division

356.7

375.2

713.9

698.8

+2.2 %

+3.0 %

Safety division

206.2

192.8

410.2

365.1

+12.4 %

+12.2 %

             
Net sales 533.1 550.8 1,033.3 1,016.7 +1.6% +2.3%

Medical division

341.4

371.1

663.0

677.2

-2.1%

-1.1%

Safety division

199.2

186.0

385.2

353.0

+9.1%

+9.1%

             
EBIT[1] 51.9 65.8 94.5 102.6 -8.0%  

Medical division

39.3

52.6

69.9

93,0

-24.8%

 

Safety division

24.2

16.6

45.8

29.3

+56.5%

 

             
EBIT margin 9.7% 11.9% 9.1% 10.1%    
Earnings after income taxes 30.4 37.2  

53.7

55.9    
EPS[2] preferred shares 1.60 2.37 2.82 3.75    
EPS[2] common shares 1.59 2.36 2.79 3.72    

 

[1] EBIT = Earnings before interest and taxes

[2] EPS = Earnings per share (in €)

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

 

Kontakt

           

Corporate Communications:

Melanie Kamann

Tel. +49 451 882-3998

melanie.kamann@draeger.com

 

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

 

 

Drägerwerk AG & Co. KGaA     

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1536117

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
31 jul
TORM-A
Mit syn på Torm, og hvorfor jeg mener der er penge at hente som investor.    Der er 95,7 mia. Torm-a..
25
31 jul
ZEAL
Mange taler om LixiLan og hvor stort det kan blive - inklusiv mig selv!   Men Zealands lidt upræcise..
23
04 aug
BAVA
hermed mit bidrag.   Kerrigsdale snakker om at man skal huske at bruge Apple to apple metoden (side ..
19
01 aug
ZEAL
Jeg skrev igår et indlæg om et projekt hos Zealand Pharma som indenfor meget overskuelig fremtid kan..
16
31 jul
 
Kan vi ikke få en service meddelelse på hvad der sker med alle de korrreanske spam indlæg der flyder..
15
29 jul
OMXC20
Delfin har et indlæg om Varoufakis fra Lars Tvede som 10 personer har tomlet op. Læren er at Varoufa..
15
03 aug
VWS
Energiwatch beskriver det ligefrem som at "Suzlon haler vinder ind på Vestas".   Hvad Børsen, Energi..
11
03 aug
TORM-A
  Et kig på prospektet i Torm       13.4.2.2 Prospective consolidated financial information for the ..
11
01 aug
EXQ
Jeg opdagede for et par uger siden at inrater.com havde lavet et system hvor man kunne oprette en mo..
11
29 jul
I:DAX
Alpe påstår ikke som dig at kunne forudsige markedet i detaljer, derimod giver han bud på sandsynlig..
11

Aktier/tendens: Flad tirsdag afløses af små stigninger

05-08-2015 08:16:45
Der ser ud til at ville blæse mere positive vinde hen over det danske aktiemarked onsdag, end der gjorde i gårsdagens småkedelige handel.Herhjemme lukkede det l..

OPTAKT Novo Q2 6/8: Vækstprognosen kan stå foran et løft

04-08-2015 12:35:31
Der er udsigt til endnu et flot regnskab fra Novo Nordisk torsdag morgen.Salget af selskabets langtidsvirkende insulin Tresiba samt diabetesmedicinen Victoza fo..

Aktier/åbning: DSV belønnes og sørger for positivt C20

04-08-2015 09:16:10
Det danske aktiemarked er tirsdag åbnet i plus, og det er i høj grad takket være DSV, som i et stærkt regnskab tirsdag morgen opjusterede forventningerne. Efter..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
OPTAKT Novo Q2 6/8: Vækstprognosen kan stå foran et løft
2
Kina/Danske Invest: Hold snitterne fra Kina-aktier
3
Rente/Nykredit: Slå til nu og tag fastforrentet lån
4
Aktier/tendens: Flad tirsdag afløses af små stigninger
5
Grækenland: Banker bankes i bund på børsen

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
5. august 2015 10:26:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150804.2 - EUROWEB2 - 2015-08-05 10:26:43 - 2015-08-05 10:26:43 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x